Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review analyzes the mechanism and evidence supporting the approved use of ritlecitinib, a JAK3/TEC kinase inhibitor, for treating severe alopecia areata in patients aged 12 and older, highlighting its role in the changing therapeutic landscape of this immune-mediated disease.

In this study, researchers developed a novel topical gel combining minoxidil and JAK inhibitor tofacitinib, which effectively enhanced hair follicle growth and reduced local inflammation in mice with alopecia areata, suggesting a new approach for treating this condition.

This study found that alopecia areata significantly impacts patients' quality of life irrespective of hair loss severity, and concluded that the newer assessment tools AAPPO and AASIS better capture this impact compared to the traditional SALT measure.

5-ARI therapy may help prevent prostate cancer progression.

This report from the seventh AA Research Summit discusses research highlights and sets future priorities for managing alopecia areata.

This study examined FAERS data and found an increasing trend in alopecia areata cases, with monoclonal antibodies most frequently linked to the condition.

This paper reviews recent advancements in understanding hair follicle structure and the role of JAKs in hair growth, though it does not report new experimental findings.

This paper discusses a consensus statement from European experts recommending systemic JAK inhibitors as first-line therapy for moderate to severe alopecia areata.

Reduced androgens linked to kinky hair disorder and hair loss; 5a-reductase inhibitors may help.

This review discusses the pathophysiology, economic burden, and treatment options of alopecia areata and reports no new clinical results, highlighting the need for better therapies, including JAK inhibitors.

This case report identifies alopecia universalis as a probable adverse drug reaction to adalimumab in a patient with psoriasis and psoriatic arthritis.

In human hair follicle keratinocytes, this study found that treatment with the pharmacological inhibitor QLT0267 led to a strong inhibition of proliferation and migration and induced nearly 100% apoptosis.

In this observational study, researchers found that socioeconomic factors and stress significantly influence alopecia areata in patients in the Indian subcontinent.

In this study, baricitinib was used as monotherapy to treat a 21-year-old woman with severe alopecia areata, resulting in significant hair regrowth and reduced alopecia severity within three months, suggesting its effectiveness and potential as a robust treatment option for this condition.

In this analysis, JAK inhibitors were found to provide clinically meaningful and durable hair regrowth in pediatric alopecia areata, outperforming traditional therapies with a manageable safety profile.

This study observed distinct post-marketing safety signal patterns for baricitinib and tofacitinib in adult AA, influenced by their differing regulatory uses and real-world contexts, and emphasizes the need for future studies to validate these findings.

This study observed that in pediatric patients with alopecia areata, severity of the condition was associated with disease duration, atopy, and nail involvement, but not with anemia.

The abstract provides a brief mention of alopecia areata (AA) being a chronic immune-mediated disorder causing non-scarring hair loss, but specific study results or findings relating to this are not reported.

JAK inhibitors are effective and generally safe for treating alopecia areata, but monitoring for side effects is important.

This study analyzed online discussions and search behavior in Gulf countries, uncovering significant engagement and identifying gaps in awareness and understanding of alopecia areata among patients and healthcare professionals, suggesting a need for targeted educational initiatives to enhance support and reduce stigma.

This study found that oral JAK inhibitors significantly improve hair regrowth in adults with moderate-to-severe alopecia areata compared to placebo, although they are associated with a higher risk of non-serious adverse events.

Alopecia areata is caused by immune system issues, and JAK inhibitors might help treat it.

This case study reported that zinc supplementation improved skin lesions and diarrhea in a 4-month-old breast-fed infant with transient acrodermatitis enteropathica, even though her serum zinc level was nearly normal.

In this study, the rs4541843 G > A variant was found to be significantly associated with increased risk and severity of alopecia areata, as well as elevated expression of hsa-miR-182-5p, suggesting their potential as molecular markers for diagnosis and severity assessment.

This study developed an in vitro model using NTERT keratinocytes expressing AEC-related TP63 mutations, which replicated skin defects observed in AEC patients and offers a valuable tool for understanding the disorder and developing new treatments.

In this study, 62.1% of Korean patients with chronic dermatologic diseases reported using complementary and alternative medicine, though many were dissatisfied with the results.

This study identified that Eda-A1 unexpectedly induces placode inhibitors dkk4 and lrp4, indicating the importance of tightly regulated signaling for proper ectodermal organ development.

This research highlights that JAK inhibitors, such as baricitinib, may effectively reverse symptoms of alopecia areata by targeting specific immune pathways, though safety and efficacy require further investigation.

This vodcast discusses various tools for assessing the severity of alopecia areata, emphasizing the importance of considering psychosocial impacts alongside physical symptoms.